{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:59:59Z","timestamp":1791309599634,"version":"4.3.1"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/ki.2014.19","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T13:42:11Z","timestamp":1394026931000},"page":"308-322","source":"Crossref","is-referenced-by-count":113,"title":["Metformin and other antidiabetic agents in renal failure patients"],"prefix":"10.1016","volume":"87","author":[{"given":"Jean-Daniel","family":"Lalau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Arnouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"De Broe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2014.19_bb0010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.ki.5002346","article-title":"When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis","volume":"72","author":"Prikis","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.19_bb0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"Group UKPDS","year":"1998","journal-title":"Lancet"},{"key":"10.1038\/ki.2014.19_bb0020","article-title":"The lactic acid myths","author":"Fitzgerald","year":"2012","journal-title":"Competitor"},{"key":"10.1038\/ki.2014.19_bb0025","doi-asserted-by":"crossref","first-page":"R502","DOI":"10.1152\/ajpregu.00114.2004","article-title":"Biochemistry of exercise-induced metabolic acidosis","volume":"287","author":"Robergs","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1038\/ki.2014.19_bb0030","series-title":"Lactate not guilty as charged","author":"Kravitz","year":"2013"},{"key":"10.1038\/ki.2014.19_bb0035","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0022-2828(77)80008-4","article-title":"Generation of protons by metabolic processes in heart cells","volume":"9","author":"Gevers","year":"1977","journal-title":"J Mol Cell Cardiol"},{"key":"10.1038\/ki.2014.19_bb0040","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1152\/ajpregu.2001.280.1.R48","article-title":"Activity-induced recovery of excitability in K(+)-depressed rat soleus muscle","volume":"280","author":"Overgaard","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1038\/ki.2014.19_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2014.19_bb0050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00228-011-1207-0","article-title":"Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus","volume":"68","author":"Bardin","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2133\/dmpk.20.379","article-title":"Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1","volume":"20","author":"Kimura","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1038\/ki.2014.19_bb0060","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1038\/ki.2014.19_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/07853890.2010.549144","article-title":"Disposition of metformin: variability due to polymorphisms of organic cation transporters","volume":"44","author":"Zolk","year":"2012","journal-title":"Ann Med"},{"key":"10.1038\/ki.2014.19_bb0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.102.034140","article-title":"Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin","volume":"302","author":"Wang","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2014.19_bb0075","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2014.19_bb0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1038\/ki.2014.19_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng.735","article-title":"Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes","volume":"43","author":"Zhou","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2014.19_bb0090","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-012-2537-x","article-title":"A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts","volume":"55","author":"van Leeuwen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0095","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","article-title":"OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine","volume":"18","author":"Wang","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1038\/ki.2014.19_bb0100","doi-asserted-by":"crossref","first-page":"e22163","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/ki.2014.19_bb0105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.23103","article-title":"Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver","volume":"50","author":"Nies","year":"2009","journal-title":"Hepatology"},{"key":"10.1038\/ki.2014.19_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00498259409043220","article-title":"Accumulation of metformin by tissues of the normal and diabetic mouse","volume":"24","author":"Wilcock","year":"1994","journal-title":"Xenobiotica"},{"key":"10.1038\/ki.2014.19_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1262-3636(07)70037-X","article-title":"Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects","volume":"29","author":"Robert","year":"2003","journal-title":"Diabetes Metab"},{"key":"10.1038\/ki.2014.19_bb0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0125","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"issue":"Pt 3","key":"10.1038\/ki.2014.19_bb0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"10.1038\/ki.2014.19_bb0135","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2014.19_bb0140","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1172\/JCI43661","article-title":"An energetic tale of AMPK-independent effects of metformin","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2014.19_bb0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1038\/ki.2014.19_bb0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1038\/ki.2014.19_bb0155","first-page":"110","article-title":"Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes","volume":"25","author":"Wiernsperger","year":"1999","journal-title":"Diabetes Metab"},{"key":"10.1038\/ki.2014.19_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10863-006-9003-8","article-title":"The ROS production induced by a reverse-electron flux at respiratory complex 1 is hampered by metformin","volume":"38","author":"Batandier","year":"2006","journal-title":"J Bioenerg Biomembr"},{"key":"10.1038\/ki.2014.19_bb0165","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/diabetes.54.7.2179","article-title":"Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process","volume":"54","author":"Detaille","year":"2005","journal-title":"Diabetes"},{"key":"10.1038\/ki.2014.19_bb0170","doi-asserted-by":"crossref","first-page":"R192","DOI":"10.1186\/cc12886","article-title":"Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study","volume":"17","author":"Christiansen","year":"2013","journal-title":"Crit Care"},{"key":"10.1038\/ki.2014.19_bb0175","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.2010.11","article-title":"Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway","volume":"77","author":"Morales","year":"2010","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.19_bb0180","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2010.11.029","article-title":"Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats","volume":"653","author":"Louro","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.19_bb0190","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/diab.46.9.1406","article-title":"Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver","volume":"46","author":"Radziuk","year":"1997","journal-title":"Diabetes"},{"key":"10.1038\/ki.2014.19_bb0195","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.annemergmed.2009.04.023","article-title":"Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature","volume":"54","author":"Dell\u2019Aglio","year":"2009","journal-title":"Ann Emerg Med"},{"key":"10.1038\/ki.2014.19_bb0200","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/diacare.21.11.2036","article-title":"Consequences of metformin intoxication","volume":"21","author":"Lalau","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0205","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/mol.63.4.844","article-title":"Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin","volume":"63","author":"Wang","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0210","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1476-5381.2012.01853.x","article-title":"Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis","volume":"166","author":"Toyama","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.taap.2008.08.013","article-title":"Biguanide-induced mitochondrial dysfonction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro","volume":"233","author":"Dykens","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0220","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/cc8885","article-title":"Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication","volume":"14","author":"Protti","year":"2010","journal-title":"Crit Care"},{"key":"10.1038\/ki.2014.19_bb0225","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/cc11332","article-title":"Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs","volume":"16","author":"Protti","year":"2012","journal-title":"Crit Care"},{"key":"10.1038\/ki.2014.19_bb0230","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc11663","article-title":"Metformin overdose causes platelet mitochondrial dysfunction in humans","volume":"16","author":"Protti","year":"2012","journal-title":"Crit Care"},{"key":"10.1038\/ki.2014.19_bb0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1463-1326.2000.00053.x","article-title":"Metformin and lactic acidosis in diabetic humans","volume":"2","author":"Lalau","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1038\/ki.2014.19_bb0240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00498250701546012","article-title":"Functional involvement of organic cation transporter1 (OCT1\/Oct1) in the hepatic uptake of organic cations in humans and rats","volume":"37","author":"Umehara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1038\/ki.2014.19_bb0245","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","article-title":"Lactic acidosis induced by metformin: incidence, management and prevention","volume":"33","author":"Lalau","year":"2010","journal-title":"Drug Saf"},{"key":"10.1038\/ki.2014.19_bb0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1463-1326.2001.00128.x","article-title":"Lactic acidosis in metformin therapy: searching for a link with metformin in reports of \u2018metformin-associated lactic acidosis\u2019","volume":"3","author":"Lalau","year":"2001","journal-title":"Diabetes Obes Metab"},{"key":"10.1038\/ki.2014.19_bb0255","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/dme.12017","article-title":"The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database","volume":"30","author":"Kajbaf","year":"2013","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2014.19_bb0260","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2796.2003.01271.x","article-title":"Metformin and lactic acidosis: cause or coincidence? A review of case reports","volume":"255","author":"Stades","year":"2004","journal-title":"J Intern Med"},{"key":"10.1038\/ki.2014.19_bb0265","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/11588310-000000000-00000","article-title":"Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations","volume":"31","author":"Lalau","year":"2011","journal-title":"Clin Drug Invest"},{"key":"10.1038\/ki.2014.19_bb0270","first-page":"24","article-title":"Metformin retention independent of renal failure in intestinal occlusion","volume":"27","author":"Lalau","year":"2001","journal-title":"Diabetes Metab"},{"key":"10.1038\/ki.2014.19_bb0275","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002018-199920040-00006","article-title":"Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations","volume":"20","author":"Lalau","year":"1999","journal-title":"Drug Saf"},{"key":"10.1038\/ki.2014.19_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2050-6511-14-22","article-title":"The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis","volume":"14","author":"Kajbaf","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1038\/ki.2014.19_bb0285","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/cc7137","article-title":"Metformin-associated lactic acidosis in an intensive care unit","volume":"12","author":"Peters","year":"2008","journal-title":"Crit Care"},{"key":"10.1038\/ki.2014.19_bb0290","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: a prognostic and therapeutic study","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1038\/ki.2014.19_bb0295","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pds.3501","article-title":"Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal from around the world","volume":"22","author":"Kajbaf","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1038\/ki.2014.19_bb0300","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-5491.1999.00115.x","article-title":"Contra-indications to metformin therapy are largely disregarded","volume":"16","author":"Holstein","year":"1999","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2014.19_bb0305","first-page":"502","article-title":"Metformin\u2019s contraindications should be contraindicated","volume":"173","author":"McCormack","year":"2005","journal-title":"CAMJ"},{"key":"10.1038\/ki.2014.19_bb0310","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/bmj.326.7379.4","article-title":"Contraindications to the use of metformin","volume":"4","author":"Jones","year":"2003","journal-title":"BMJ"},{"key":"10.1038\/ki.2014.19_bb0315","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: the safest hypoglycaemic agent in chronic kidney disease?","volume":"118","author":"Nye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2014.19_bb0320","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"key":"10.1038\/ki.2014.19_bb0325","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2014.19_bb0330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10557-012-6425-x","article-title":"Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon","volume":"27","author":"Whittington","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1038\/ki.2014.19_bb0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndtplus\/sfr134","article-title":"Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease","volume":"5","author":"Briet","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1038\/ki.2014.19_bb0340","first-page":"329","article-title":"Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly)","volume":"28","author":"Lalau","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1038\/ki.2014.19_bb0345","first-page":"34","article-title":"Complications associated with new-onset diabetes after kidney transplantation","volume":"15","author":"Sharif","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1038\/ki.2014.19_bb0350","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1600-6143.2011.03855.x","article-title":"New-onset diabetes after kidney transplantation\u2014changes and challenges","volume":"12","author":"Yates","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.19_bb0355","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/TP.0b013e3182347ea4","article-title":"Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation","volume":"92","author":"Lane","year":"2011","journal-title":"Transplantation"},{"key":"10.1038\/ki.2014.19_bb0360","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1600-6143.2006.01250.x","article-title":"Repaglinide in the management of new-onset diabetes mellitus after renal transplantation","volume":"6","author":"Turk","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.19_bb0365","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1432-2277.2004.00076.x","article-title":"Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation","volume":"18","author":"Pietruck","year":"2005","journal-title":"Transpl Int"},{"key":"10.1038\/ki.2014.19_bb0370","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"issue":"10 Suppl","key":"10.1038\/ki.2014.19_bb0375","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"10.1038\/ki.2014.19_bb0380","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1600-6143.2011.03550.x","article-title":"Should metformin be our antiglycemic agent of choice post-transplantation?","volume":"11","author":"Sharif","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.19_bb0385","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4158\/EP.14.8.979","article-title":"Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients","volume":"14","author":"Kurian","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1038\/ki.2014.19_bb0390","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1600-6143.2011.03921.x","article-title":"Potential risks of metformin in transplant patients","volume":"12","author":"Larsen","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.19_bb0395","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1600-6143.2011.03920.x","article-title":"Metformin safety post-transplantation\u2014trials and tribulations","volume":"12","author":"Sharif","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2014.19_bb0400","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc12-1894","article-title":"Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation","volume":"36","author":"Zelle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0405","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfs583","article-title":"Novel views on new-onset diabetes after transplantation: development, prevention and treatment","volume":"28","author":"Hecking","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.19_bb0410","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.19_bb0415","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/TP.0b013e318260b1e9","article-title":"Clinical trials for treatment of NODAT\u2014time to collaborate","volume":"94","author":"Sharif","year":"2012","journal-title":"Transplantation"},{"key":"10.1038\/ki.2014.19_bb0420","first-page":"6S117","article-title":"Metformin and vascular protection: a cardiologist\u2019s view","volume":"29","author":"Libby","year":"2003","journal-title":"Diabetes Met"},{"key":"10.1038\/ki.2014.19_bb0425","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1463-1326.2012.01604.x","article-title":"Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis","volume":"14","author":"Pantalone","year":"2012","journal-title":"Diab Obes Metab"},{"key":"10.1038\/ki.2014.19_bb0430","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00125-013-2958-1","article-title":"Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy","volume":"56","author":"Wheeler","year":"2013","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0435","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0440","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/pds.3432","article-title":"Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control","volume":"22","author":"Hung","year":"2013","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1038\/ki.2014.19_bb0445","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0450","first-page":"CD002966","article-title":"Metformin monotherapy for diabetes mellitus","volume":"30","author":"Saenz","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/ki.2014.19_bb0455","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/msj.20116","article-title":"Balancing risk and benefit with oral hypoglycemic drugs","volume":"76","author":"Hamnvik","year":"2009","journal-title":"Mt Sinai J Med"},{"key":"10.1038\/ki.2014.19_bb0460","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1525-139x.2000.00007.x","article-title":"Impact of end-stage renal disease on glycemic control","volume":"13","author":"Mak","year":"2000","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2014.19_bb0465","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.2011.939","article-title":"Diabetes drug may be associated with increase in risk of bladder cancer","volume":"306","author":"Stephenson","year":"2011","journal-title":"JAMA"},{"key":"10.1038\/ki.2014.19_bb0470","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0475","article-title":"Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties","author":"Arnouts","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.19_bb0480","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0272-6386(00)70204-6","article-title":"Prolonged SU-induces hypoglycaemia in diabetic patients with ESRD","volume":"35","author":"Krepinsky","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.19_bb0485","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0272-6386(97)90465-0","article-title":"Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure","volume":"29","author":"Brier","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.19_bb0490","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s001250050624","article-title":"Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment","volume":"39","author":"Rosenkranz","year":"1996","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0495","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00228-003-0592-4","article-title":"Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycemia","volume":"59","author":"Holstein","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0500","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2165\/00003495-199346010-00007","article-title":"Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus","volume":"46","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1038\/ki.2014.19_bb0505","series-title":"Gliclazide and the treatment of diabetes mellitus","first-page":"71","article-title":"Pharmacokinetics and Metabolism of Gliclazide: A Review","author":"Campbell","year":"1980"},{"key":"10.1038\/ki.2014.19_bb0510","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF01218443","article-title":"Pharmacokinetics in man: influence of renal insufficiency","volume":"9","author":"Balant","year":"1973","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0515","first-page":"247","article-title":"Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus","volume":"47","author":"Von Nicolai","year":"1997","journal-title":"Arzneimittel Forschung"},{"key":"10.1038\/ki.2014.19_bb0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-199631020-00003","article-title":"Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency","volume":"31","author":"Harrower","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2014.19_bb0525","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0530","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1067\/mcp.2000.103973","article-title":"Pharmacokinetics of repaglinide in subjects with renal impairment","volume":"67","author":"Marbury","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/ki.2014.19_bb0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002280100280","article-title":"Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment","volume":"57","author":"Schumacher","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0540","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"Inoue","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2014.19_bb0545","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(02)00242-5","article-title":"Hypoglycemia due to nateglinide administration in diabetic patients with chronic renal failure","volume":"59","author":"Nagai","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1038\/ki.2014.19_bb0550","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000186953","article-title":"Glucose and insulin metabolism in uremia","volume":"61","author":"Mak","year":"1992","journal-title":"Nephron"},{"key":"10.1038\/ki.2014.19_bb0555","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.24.5.886","article-title":"Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients","volume":"24","author":"Rave","year":"2001","journal-title":"Diab Care"},{"key":"10.1038\/ki.2014.19_bb0560","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1464-5491.2003.01025.x","article-title":"Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients","volume":"20","author":"Biesenbach","year":"2003","journal-title":"Diabet Med"},{"key":"10.1038\/ki.2014.19_bb0565","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.19_bb0570","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes mellitus","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.19_bb0575","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2337\/dc06-2545","article-title":"Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-IV inhibitor","volume":"30","author":"Bergman","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2014.19_bb0580","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","article-title":"Safety and efficacy of sitagliptine in patients with type 2 diabetes and chronic renal insufficiency","volume":"10","author":"Chan","year":"2008","journal-title":"Diab Obesity Met"},{"key":"10.1038\/ki.2014.19_bb0585","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/dmd.108.023010","article-title":"Absorption, metabolism, and excretion of (14C)vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans","volume":"37","author":"He","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/ki.2014.19_bb0590","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidyl peptidase inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1038\/ki.2014.19_bb0595","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/11584350-000000000-00000","article-title":"Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin","volume":"50","author":"Boulton","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2014.19_bb0600","first-page":"1091","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"10","author":"Tiwari","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1038\/ki.2014.19_bb0605","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12325-011-0028-y","article-title":"Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy","volume":"28","author":"Barnett","year":"2011","journal-title":"Adv Ther"},{"key":"10.1038\/ki.2014.19_bb0610","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/ki.2014.19_bb0615","author":"Graefe-Mody","year":"2010"},{"key":"10.1038\/ki.2014.19_bb0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1038\/ki.2014.19_bb0625","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0630","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138920006776873490","article-title":"Investigation of exenatide elimination and its in vivo and in vitro degradation","volume":"7","author":"Copley","year":"2006","journal-title":"Current Drug Metabolism"},{"key":"10.1038\/ki.2014.19_bb0635","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2014.19_bb0640","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjefalt","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/ki.2014.19_bb0645","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobson","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2014.19_bb0650","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"Budde","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl. 4","key":"10.1038\/ki.2014.19_bb0655","first-page":"73","article-title":"Management of drugs affecting blood glucose in diabetic patients with renal failure","volume":"26","author":"Charpentier","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1038\/ki.2014.19_bb0660","first-page":"734","article-title":"Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man","volume":"47","author":"Ahr","year":"1997","journal-title":"Azrneimittelforschung"},{"key":"10.1038\/ki.2014.19_bb0665","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney International"},{"key":"10.1038\/ki.2014.19_bb0670","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-013-0064-9","article-title":"Canagliflozin: First Global Approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"10.1038\/ki.2014.19_bb0675","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2147\/DDDT.S48937","article-title":"Canagliflozin: a novel treatment option for type 2 diabetes","volume":"7","author":"Dietrich","year":"2013","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1038\/ki.2014.19_bb0680","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2014.19_bb0685","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T01:25:11Z","timestamp":1597541111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0085253815300429"],"URL":"https:\/\/doi.org\/10.1038\/ki.2014.19","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}